Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | HAAO | P46952 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28719291 | 0.83 | MAP2K1 (0.34) | BRD4GPR35MAOBL3MBTL1 | |
| SCHEMBL22729476 | 0.76 | BRD4 (0.31) | BRD4 | |
| SCHEMBL28723227 | 0.76 | BRD4 (0.37) | HPGDLMNABRD4MAOBL3MBTL1 | |
| SCHEMBL28723229 | 0.74 | BRD4 (0.34) | LMNABRD4MAOBL3MBTL1KDM4E | |
| SCHEMBL22729514 | 0.72 | NOTUM (0.37) | NOTUMHPGDBCAT2LMNABRD4 | |
| SCHEMBL22729825 | 0.72 | ALDH1A1 (0.41) | BRD4KDM4EGAA | |
| SCHEMBL22729400 | 0.69 | BCAT2 (0.38) | NOTUMHPGDBCAT2LMNABRD4 | |
| SCHEMBL23212251 | 0.69 | BRD4 (0.44) | HPGDLMNABRD4SMN1; SMN2KDM4E | |
| SCHEMBL22729432 | 0.67 | LMNA (0.40) | NOTUMHPGDLMNABRD4KDM4E | |
| SCHEMBL22729865 | 0.67 | ATM (0.37) | NOTUMHPGDBCAT2LMNABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | NOTUM 757/4885HPGD 1589/4885BCAT2 1447/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | NOTUM 715/4885HPGD 1502/4885BCAT2 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.